141 related articles for article (PubMed ID: 25815756)
41. Antidepressant discontinuation syndrome.
Antai-Otong D
Perspect Psychiatr Care; 2003; 39(3):127-8. PubMed ID: 14606234
[No Abstract] [Full Text] [Related]
42. [Adverse effects: priapism caused by paroxetine].
Bertholon F; Krajewski Y; el Allali A
Ann Med Psychol (Paris); 1996 May; 154(2):145-6; discussion 146-7. PubMed ID: 8694403
[TBL] [Abstract][Full Text] [Related]
43. Drugs associated with restless legs syndrome: a case/noncase study in the French Pharmacovigilance Database.
Perez-Lloret S; Rey MV; Bondon-Guitton E; Rascol O; Montastruc AJ;
J Clin Psychopharmacol; 2012 Dec; 32(6):824-7. PubMed ID: 23131889
[TBL] [Abstract][Full Text] [Related]
44. [Restless legs syndrome and psychiatric diseases].
Sforza E; Cervena K
Rev Med Suisse; 2006 Sep; 2(79):2108-10, 2112-4. PubMed ID: 17073178
[TBL] [Abstract][Full Text] [Related]
45. Duloxetine-induced life-threatening long QT syndrome.
Štuhec M
Wien Klin Wochenschr; 2013 Mar; 125(5-6):165-6. PubMed ID: 23440523
[No Abstract] [Full Text] [Related]
46. Oxcarbazepine treatment for paroxetine-induced restless leg syndrome.
Oztürk O; Eraslan D; Kumral E
Gen Hosp Psychiatry; 2006; 28(3):264-5. PubMed ID: 16675374
[No Abstract] [Full Text] [Related]
47. Duloxetine treatment of pediatric chronic pain and co-morbid major depressive disorder.
Meighen KG
J Child Adolesc Psychopharmacol; 2007 Feb; 17(1):121-7. PubMed ID: 17343560
[TBL] [Abstract][Full Text] [Related]
48. A case with occurring adverse effects when cross-over titration from fluvoxamine to paroxetine associated with increasing the plasma fluvoxamine level in major depressive disorder.
Hori H; Yoshimura R; Ueda N; Ikenouchi-Sugita A; Umene-Nakano W; Nakamura J
World J Biol Psychiatry; 2009; 10(4 Pt 2):620-2. PubMed ID: 18609433
[TBL] [Abstract][Full Text] [Related]
49. [Paroxetine augmentation with risperidone in therapy-resistant depression].
Knopf U; Hubrich-Ungureanu P; Thome J
Psychiatr Prax; 2001 Nov; 28(8):405-6. PubMed ID: 11721229
[TBL] [Abstract][Full Text] [Related]
50. [Efficacy and tolerability of paroxetine in the treatment of the depressive phase of bipolar disorders].
Ambrosio LA; Buccomino D; Filippo A; Morelli A; Musacchio R; Pupo F; Romano FE; Marchese G; Barrese E
Minerva Psichiatr; 1996 Jun; 37(2):91-7. PubMed ID: 8926862
[TBL] [Abstract][Full Text] [Related]
51. Improving antidepressant adherence.
Nemeroff CB
J Clin Psychiatry; 2003; 64 Suppl 18():25-30. PubMed ID: 14700452
[TBL] [Abstract][Full Text] [Related]
52. Duloxetine-induced subcortical growth in a patient with major depressive disorder and panic disorder.
Lai CH
J Neuropsychiatry Clin Neurosci; 2011; 23(2):E42-3. PubMed ID: 21677225
[No Abstract] [Full Text] [Related]
53. Maintained superiority of chronotherapeutics vs. exercise in a 20-week randomized follow-up trial in major depression.
Martiny K; Refsgaard E; Lund V; Lunde M; Thougaard B; Lindberg L; Bech P
Acta Psychiatr Scand; 2015 Jun; 131(6):446-57. PubMed ID: 25689725
[TBL] [Abstract][Full Text] [Related]
54. Safety of electroconvulsive therapy-duloxetine combination.
Eraslan D; Genc Y; Odabasioglu G; Ergun BM; Ozturk O
J ECT; 2011 Sep; 27(3):e51-2. PubMed ID: 21865952
[No Abstract] [Full Text] [Related]
55. Duloxetine Hydrochloride-Induced Oral Lichenoid Reaction: A Case Report.
Kadam NS; Patil RA; Gurav AN; Shete A; Jadhav PD; Naik Tari R; Metkari S; Agarwal D
Med Princ Pract; 2015; 24(4):394-7. PubMed ID: 26022117
[TBL] [Abstract][Full Text] [Related]
56. Duloxetine-related growth of putamen and brainstem in first-onset drug-naive major depressive disorder with panic disorder: a case series.
Lai CH
J Neuropsychiatry Clin Neurosci; 2011; 23(2):E40-1. PubMed ID: 21677224
[No Abstract] [Full Text] [Related]
57. Duloxetine-related posterior reversible encephalopathy syndrome: A case report.
Zappella N; Perier F; Pico F; Palette C; Muret A; Merceron S; Girbovan A; Marquion F; Legriel S
Medicine (Baltimore); 2016 Aug; 95(33):e4556. PubMed ID: 27537580
[TBL] [Abstract][Full Text] [Related]
58. Treatment of depression in patients with restless legs syndrome: what is evidence-based?
Hornyak M; Voderholzer U; Riemann D
Sleep Med; 2006 Apr; 7(3):301-2; author reply 303-4. PubMed ID: 16564207
[No Abstract] [Full Text] [Related]
59. Improvement of acne in depressed patients treated with paroxetine.
Moussavian H
J Am Acad Child Adolesc Psychiatry; 2001 May; 40(5):505-6. PubMed ID: 11349692
[No Abstract] [Full Text] [Related]
60. [With the Characteristics of Chronic Pain Patients, Can the Therapeutic Effect of Antidepressant Duloxetine be Predicted?].
Enomoto T; Sugita M; Katsuta Y; Hori N; Koh K; Saito R; Hasegawa R; Takahashi Y; Sugasawa Y; Yamaguchi K; Isek M; Inada E
Masui; 2016 Oct; 65(10):1005-1008. PubMed ID: 30358274
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
